Kymera Stock 130%: $135 Million Buy Boosts Immunology Bet
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
Volatility-adjusted returns show how total market funds stack up against SP 500 over time, highlighting stability versus peak swings for retirement savings.
28,240 articlesA major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
Upstart’s growth engine faces higher costs that squeeze margins, triggering a drop in price even when revenue beats. ...
Understanding James River (JRVR) earnings means decoding insurance results, investment income, and risk management. T...
Carl Icahn’s latest stake move in Icahn Enterprises drew attention from investors. This article breaks down what icah...
Across software-as-a-service stocks, Wix has been a standout case of a dramatic pullback. This piece breaks down why ...
As Nvidia captures headlines with its chips, two AI software plays are quietly building durable demand. This article ...
Strategy reveals a fresh BTC buy totaling $1.28 billion, boosting its total stash to 738,731 BTC and signaling contin...
A recent insider move at Lindblad Expeditions Holdings drew attention from investors. This article breaks down what h...
A sweeping change is quietly redefining housing. This article explains the $48t “structural shift” housing and why it...
When a company’s founder and CEO sells a chunk of stock, investors want to know what it means for future performance....
A new northwestern mutual 2025 study exposes a sharp mismatch: Millennials prize wealth transfer yet most have not se...